Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Blood (2024) 143 (11): 1006–1017.

https://doi.org/10.1182/blood.2023020515

Published: 2024

Includes: Supplemental data

Journal Articles

Distinct Subtypes of Chemotherapy-Resistant Systemic ALK-Positive Anaplastic Large Cell Lymphoma Demonstrate Long-Term Complete Remissions to Imatinib

Alexander Pichler, Christoph Kornauth, Ines Garces De Los Fayos Alonso, Lukas Kazianka, Arne Zibat, Luca Mologni, Halima Alachram, Tea Pemovska, Gerwin Heller, Richard Greil, Lukas Kenner, Ulrich Jaeger, Philipp Bernhard Staber

Blood (2023) 142 (Supplement 1): 1691.

https://doi.org/10.1182/blood-2023-188835

Published: 2023

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

The Integrin Adaptor Kindlin-3 Is Important for Development and Retention of Marginal Zone B Cells

Andrea Härzschel, Peter William Krenn, Elisabeth Bayer, Simone Tangermann, Geoffroy Andrieux, Elif Karabatak, Eva Szenes, Danielle-Justine Danner, Ursula Denk, Raphael Ruppert, Alexander Egle, MD, Richard Greil, MD, Lukas Kenner, MD, Melanie Boerries, MD PhD, Tanja Nicole Hartmann, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136905

Published: 2020

Journal Articles

IL10RA modulates crizotinib sensitivity in NPM1-ALK + anaplastic large cell lymphoma

Blood (2020) 136 (14): 1657–1669.

https://doi.org/10.1182/blood.2019003793

Published: 2020

Includes: Supplemental data

Journal Articles

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Philipp Bernhard Staber, MD PhD, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, MD, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, PhD, Marius E Mayerhoefer, Richard Greil, MD, Ingrid Simonitsch-Klupp, MD, Lukas Kenner, MD, Ulrich Jaeger, MD

Blood (2019) 134 (Supplement_1): 4037.

https://doi.org/10.1182/blood-2019-129955

Published: 2019

Journal Articles

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

Stephen P. Ducray, BSc, Ricky Trigg, PhD, Andrew J. Bannister, PhD, Raymond Lai, MD PhD FRCP, Gerda Egger, PhD, Olaf Merkel, PhD, Lukas Kenner, MD, Suzanne Turner, PhD

Blood (2019) 134 (Supplement_1): 1483.

https://doi.org/10.1182/blood-2019-125648

Published: 2019

Journal Articles

Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells

Stefanie Sperling, Petra Fiedler, Markus Lechner, Anna Pollithy, Stefanie Ehrenberg, Ana-Iris Schiefer, Lukas Kenner, Annette Feuchtinger, Ralf Kühn, Gene Swinerd, Marc Schmidt-Supprian, Lothar J. Strobl, Ursula Zimber-Strobl

Blood (2019) 133 (24): 2597–2609.

https://doi.org/10.1182/blood.2018880138

Published: 2019

Includes: Supplemental data

Journal Articles

Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia

Julia C. Gutjahr, Eva Szenes, Lisa Tschech, Daniela Asslaber, Michaela Schlederer, Simone Roos, Xiaobing Yu, Tamara Girbl, Christina Sternberg, Alexander Egle, Fritz Aberger, Ronen Alon, Lukas Kenner, Richard Greil, Veronique Orian-Rousseau, Tanja N. Hartmann

Blood (2018) 131 (12): 1337–1349.

https://doi.org/10.1182/blood-2017-08-802462

Published: 2018

Includes: Supplemental data

Journal Articles

First in Human Response of BCL-2 Inhibitor Venetoclax in T-Cell Prolymphocytic Leukemia

Bernd Boidol, Christoph Kornauth, MD, Emiel van der Kouwe, Nicole Prutsch, Lukas Kazianka, MD, Gregor Hoermann, MD, Georg Hopfinger, MD, Alexander Hauswirth, MD, Marie-Bernadette Aretin, Wolfgang R. Sperr, MD, Peter Valent, MD, Ingrid Simonitsch-Klupp, MD, Richard Morrigl, PhD, Olaf Merkel, PhD, Lukas Kenner, MD, Ulrich Jaeger, MD, Stefan Kubicek, PhD, Philipp Bernhard Staber, MD PhD

Blood (2017) 130 (Supplement 1): 575.

https://doi.org/10.1182/blood.V130.Suppl_1.575.575

Published: 2017

Journal Articles

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 855.

https://doi.org/10.1182/blood.V130.Suppl_1.855.855

Published: 2017

Journal Articles

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

Blood (2017) 130 (23): 2499–2503.

https://doi.org/10.1182/blood-2017-05-785683

Published: 2017

Includes: Supplemental data

Journal Articles

CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis

Georg Greiner, Nadine Witzeneder, Angelika Berger, Klaus Schmetterer, Gregor Eisenwort, Ana-Iris Schiefer, Simone Roos, Theresia Popow-Kraupp, Leonhard Müllauer, Johannes Zuber, Veronika Sexl, Lukas Kenner, Wolfgang R. Sperr, Peter Valent, Matthias Mayerhofer, Gregor Hoermann

Blood (2017) 129 (3): 371–382.

https://doi.org/10.1182/blood-2016-09-739003

Published: 2017

Includes: Supplemental data

Journal Articles

High Expression of AF1q Is an Adverse Prognostic Factor in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation

Shotaro Hagiwara, Ana-Iris Schiefer, MD, Sohtaro MINE, MD BPharm, BA, Lukas Kenner, MD, PhD, William Tse, MD FACP

Blood (2015) 126 (23): 5321.

https://doi.org/10.1182/blood.V126.23.5321.5321

Published: 2015

Journal Articles

Convergent Mutations and New Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

Blood (2014) 124 (21): 781.

https://doi.org/10.1182/blood.V124.21.781.781

Published: 2014

Journal Articles

Generation of a Transgenic Mouse with Inducible Constitutively Active Stat5a,

Harini Nivarthi, Andriy Tsyrulnyk, Wolfgang Warsch, Zhengqi Wang, Susanne Winkler, Lukas Kenner, MD, Mathias Müller, DVM, Christopher Baum, MD, Kevin D. Bunting, PhD, Veronika Sexl, MD, Thomas Rülicke, D.V.M., Richard Moriggl, PhD

Blood (2011) 118 (21): 3399.

https://doi.org/10.1182/blood.V118.21.3399.3399

Published: 2011

Journal Articles

New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas

Lukas Kenner, Daniela Laimer, Helmut Dolznig, Paul Vesely, Karoline Kollmann, Ana-Iris Iris Schiefer, Veronika Sexl, MD, Philipp B Staber, M.D., Gerald Hoefler, Josef Penninger, Giorgio Inghirami, Jaeger Ulrich

Blood (2011) 118 (21): 1659.

https://doi.org/10.1182/blood.V118.21.1659.1659

Published: 2011

Journal Articles

Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade

Noria Harir, Cédric Boudot, Katrin Friedbichler, Karoline Sonneck, Rudin Kondo, Séverine Martin-Lannerée, Lukas Kenner, Marc Kerenyi, Saliha Yahiaoui, Valérie Gouilleux-Gruart, Jean Gondry, Laurence Bénit, Isabelle Dusanter-Fourt, Kaïss Lassoued, Peter Valent, Richard Moriggl, Fabrice Gouilleux

Blood (2008) 112 (6): 2463–2473.

https://doi.org/10.1182/blood-2007-09-115477

Published: 2008

Includes: Supplemental data

Journal Articles

The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling

Philipp B. Staber, Paul Vesely, Naznin Haq, Rene G. Ott, Kotaro Funato, Isabella Bambach, Claudia Fuchs, Silvia Schauer, Werner Linkesch, Andelko Hrzenjak, Wilhelm G. Dirks, Veronika Sexl, Helmut Bergler, Marshall E. Kadin, David W. Sternberg, Lukas Kenner, Gerald Hoefler

Blood (2007) 110 (9): 3374–3383.

https://doi.org/10.1182/blood-2007-02-071258

Published: 2007

Includes: Supplemental data

Journal Articles

NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Exerts Its Transforming Potential by Increasing Translation of JUNB through mTOR and S6K1.

Philipp B. Staber, MD, Paul Vesely, MS, Rene Ott, PhD, Naznin Haq, Werner Linkesch, MD, Silvia Schauer, Andelko Hrzenjak, PhD, Lukas Kenner, MD, Wilhelm Dirks, PhD, Marshall E. Kadin, MD, David W. Sternberg, MD PhD, Gerald Hoefler, MD

Blood (2006) 108 (11): 1428.

https://doi.org/10.1182/blood.V108.11.1428.1428

Published: 2006

NARROW

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Distinct Subtypes of Chemotherapy-Resistant Systemic ALK-Positive Anaplastic Large Cell Lymphoma Demonstrate Long-Term Complete Remissions to Imatinib

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

The Integrin Adaptor Kindlin-3 Is Important for Development and Retention of Marginal Zone B Cells

IL10RA modulates crizotinib sensitivity in NPM1-ALK + anaplastic large cell lymphoma

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells

Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia

First in Human Response of BCL-2 Inhibitor Venetoclax in T-Cell Prolymphocytic Leukemia

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis

High Expression of AF1q Is an Adverse Prognostic Factor in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation

Convergent Mutations and New Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

Generation of a Transgenic Mouse with Inducible Constitutively Active Stat5a,

New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas

Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade

The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling

NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Exerts Its Transforming Potential by Increasing Translation of JUNB through mTOR and S6K1.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only